全文获取类型
收费全文 | 90586篇 |
免费 | 6978篇 |
国内免费 | 2024篇 |
专业分类
耳鼻咽喉 | 163篇 |
儿科学 | 2455篇 |
妇产科学 | 5209篇 |
基础医学 | 5580篇 |
口腔科学 | 1139篇 |
临床医学 | 9839篇 |
内科学 | 26037篇 |
皮肤病学 | 557篇 |
神经病学 | 2164篇 |
特种医学 | 1184篇 |
外科学 | 5379篇 |
综合类 | 15421篇 |
现状与发展 | 7篇 |
一般理论 | 3篇 |
预防医学 | 8153篇 |
眼科学 | 1827篇 |
药学 | 9258篇 |
57篇 | |
中国医学 | 4450篇 |
肿瘤学 | 706篇 |
出版年
2024年 | 109篇 |
2023年 | 1665篇 |
2022年 | 2298篇 |
2021年 | 3983篇 |
2020年 | 3862篇 |
2019年 | 3264篇 |
2018年 | 3240篇 |
2017年 | 3234篇 |
2016年 | 3527篇 |
2015年 | 3394篇 |
2014年 | 6338篇 |
2013年 | 6891篇 |
2012年 | 5766篇 |
2011年 | 6253篇 |
2010年 | 4839篇 |
2009年 | 4874篇 |
2008年 | 4492篇 |
2007年 | 4410篇 |
2006年 | 3812篇 |
2005年 | 3326篇 |
2004年 | 2764篇 |
2003年 | 2202篇 |
2002年 | 1737篇 |
2001年 | 1621篇 |
2000年 | 1406篇 |
1999年 | 1072篇 |
1998年 | 780篇 |
1997年 | 703篇 |
1996年 | 591篇 |
1995年 | 681篇 |
1994年 | 644篇 |
1993年 | 575篇 |
1992年 | 507篇 |
1991年 | 430篇 |
1990年 | 404篇 |
1989年 | 399篇 |
1988年 | 362篇 |
1987年 | 283篇 |
1986年 | 246篇 |
1985年 | 348篇 |
1984年 | 332篇 |
1983年 | 155篇 |
1982年 | 257篇 |
1981年 | 172篇 |
1980年 | 212篇 |
1979年 | 122篇 |
1978年 | 132篇 |
1977年 | 86篇 |
1976年 | 79篇 |
1975年 | 63篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
11.
目的探讨采用基于"人工智能(AI)的骨龄辅助评价系统(上海初云医疗科技有限公司与四川大学华西第二医院合作开发)"(以下简称为AI系统)对完全性生长激素缺乏症(CGHD)患儿诊断及骨龄评价准确性。 方法选择2014年7月至2019年11月,于四川大学华西第二医院确诊的66例来自四川地区CGHD患儿为研究对象,纳入研究组。选择同期于病例收集医院儿童保健科进行骨龄测定的67例来自四川地区身高达标儿童作为对照,纳入对照组。对每例受试儿进行左手腕关节正位X射线摄片骨龄测定,由2位医师采用《TW2骨龄评分法中国未成年人南方标准》(以下简称为TW2CHN)》与《TW3骨龄评分法标准》(以下简称为TW3),盲法评价受试儿TW2CHN-桡、尺、掌指骨(RUS)与TW2CHN-腕骨(carpal)、TW2CHN-20、TW3-RUS及TW3-carpal骨龄(以下简称为5种传统骨龄),以及以同性别、年龄身高达标儿童5种传统骨龄为标准,计算受试儿5种传统骨龄百分位数。同时,采用AI系统分别对每例受试儿采取TW2CHN与TW3法,评价其AI-TW2CHN-RUS、AI-TW2CHN-carpal、AI-TW2CHN-20、AI-TW3-RUS及AI-TW3-carpal骨龄(以下简称为5种AI骨龄)及其相应百分位数。以上述5种传统骨龄+5种AI骨龄(以下简称为10种骨龄)相应的P50、P25、P10、P3值(统称为Pn值)作为诊断CGHD患儿临界值,分别计算其诊断CGHD患儿的敏感度、特异度、约登(Youden)指数、准确率、阳性似然比、阴性似然比、阳性预测值、阴性预测值。采用Kappa值评价2组受试儿5种传统骨龄百分位数与对应的5种AI骨龄百分位数评价结果的一致性,以及2位医师对2组受试儿TW2CHN-RUS骨龄百分位数评价结果一致性。绘制上述10种骨龄百分位数诊断CGHD患儿的受试者工作特征(ROC)曲线,并计算曲线下面积(AUC)。采用配对t检验,对2组受试儿TW2CHN骨龄与TW3骨龄进行比较。本研究遵循的程序符合2013年新修订的《世界医学协会赫尔辛基宣言》要求。2组受试儿年龄、性别构成比等一般临床资料比较,差异均无统计学意义(P>0.05)。 结果①采用10种骨龄的Pn值分别作为诊断CGHD临界值,对133例受试儿CGHD诊断结果显示,除了TW3-RUS骨龄中,以骨龄≤P10作为诊断CGHD患儿临界值时的诊断准确率最高(85.0%),TW2CHN-RUS、TW2CHN-carpal、TW2CHN-20、TW3-carpal、AI-TW2CHN-RUS、AI-TW2CHN-carpal、AI-TW2CHN-20、AI-TW3-carpal、AI-TW3-RUS骨龄中,均为以骨龄≤P25作为临界值时,对CGHD的诊断准确率最高,分别为81.9%、75.2%、88.0%、78.2%、75.2%、73.6%、81.2%、72.9%、78.9%。②一致性检验结果显示,2组受试儿TW2CHN-RUS与AI-TW2CHN-RUS、TW2CHN-carpal与AI-TW2CHN-carpal、TW2CHN-20与AI-TW2CHN-20、TW3-RUS与AI-TW3-RUS、TW3-carpal与AI-TW3-carpal骨龄百分位数评价结果均为中等一致性,Kappa值分别为0.445、0.578、0.570、0.446、0.430(均为P<0.001)。③对2位医师对2组受试儿TW2CHN-RUS骨龄百分位数评价结果进行一致性检验显示,其Kappa值为0.790(P<0.001),一致性较高。④绘制10种骨龄百分位数评价结果诊断CGHD的ROC曲线分析结果显示,TW2CHN-RUS、TW2CHN-carpal、TW2CHN-20、TW3-carpal、TW3-RUS、AI-TW2CHN-RUS、AI-TW2CHN-carpal、AI-TW2CHN-20、AI-TW3-carpal、AI-TW3-RUS骨龄百分位数诊断CGHD患儿的AUC分别为0.932、0.859、0.915、0.895、0.844、0.823、0.805、0.866、0.860、0.764(均为P<0.001)。⑤133例受试儿的TW3-RUS、TW3-carpal、AI-TW3-RUS、AI-TW3-carpal骨龄,均分别显著低于TW2CHN-RUS、TW2CHN-carpal、AI-TW2CHN-RUS、AI-TW2CHN-carpal骨龄,并且差异均有统计学意义(t=21.746、25.287、16.498、9.290,P<0.001)。 结论TW2CHN法、TW3法对CGHD患儿骨龄评价及诊断均有临床价值,TW2CHN-RUS骨龄对于CGDH患儿诊断效能高。四川地区儿童TW3骨龄较TW2CHN骨龄低,TW3法可能不完全适用于四川地区儿童骨龄评价。AI系统对于四川地区CGHD患儿骨龄评价结果与传统骨龄评价结果具有中等一致性,可为临床医师评价受试儿骨龄提供帮助。 相似文献
12.
《Clínica e investigación en ginecología y obstetricia》2022,49(2):100734
Acute myeloid leukaemia (AML) is one of the deadliest haematological malignancies. During pregnancy it is a rare comorbidity and can lead to adverse outcomes, such as death, without adequate treatment. The management of AML during pregnancy remains a challenge. We report the case of a primigravida 34-year-old, with 18 weeks of amenorrhoea, who attended the emergency department presenting with pain and hypertrophy of the oral mucosa, accompanied by intense asthenia. Acute myeloblastic leukaemia was diagnosed. The possibility of terminating the pregnancy was offered given the lack of evidence regarding the maternal-foetal outcome, but the patient rejected it, so chemotherapy treatment was started. In the ultrasound controls there was no evidence of teratogenic alterations nor foetal growth restriction, and there were no alterations in Doppler flow values. It was decided to end the pregnancy at 32 + 3 GW. A preterm male was born through eutocic delivery with a normal Apgar test and umbilical cord pH, and did not require resuscitation. The puerperium was favourable and 15 days following discharge she was admitted for a bone marrow transplant from her HLA identical sister. The patient died due to rejection of the transplant and the complications derived from this event. 相似文献
13.
14.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
15.
《Value in health》2022,25(7):1235-1252
ObjectivesThe incidence of type 1 diabetes mellitus is increasing every year requiring substantial expenditure on treatment and complications. A systematic review was conducted on the cost-effectiveness of insulin formulations, including ultralong-, long-, or intermediate-acting insulin, and their biosimilar insulin equivalents.MethodsMEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, HTA, and NHS EED were searched from inception to June 11, 2021. Cost-effectiveness and cost-utility analyses were included if insulin formulations in adults (≥ 16 years) with type 1 diabetes mellitus were evaluated. Two reviewers independently screened titles, abstracts, and full-text articles, extracted study data, and appraised their quality using the Drummond 10-item checklist. Costs were converted to 2020 US dollars adjusting for inflation and purchasing power parity across currencies.ResultsA total of 27 studies were included. Incremental cost-effectiveness ratios ranged widely across the studies. All pairwise comparisons (11 of 11, 100%) found that ultralong-acting insulin was cost-effective compared with other long-acting insulins, including a long-acting biosimilar. Most pairwise comparisons (24 of 27, 89%) concluded that long-acting insulin was cost-effective compared with intermediate-acting insulin. Few studies compared long-acting insulins with one another.ConclusionsLong-acting insulin may be cost-effective compared with intermediate-acting insulin. Future studies should directly compare biosimilar options and long-acting insulin options and evaluate the long-term consequences of ultralong-acting insulins. 相似文献
16.
17.
18.
《Obesity research & clinical practice》2022,16(1):44-49
BackgroundPre-pregnancy obesity is a well-recognized risk factor for gestational diabetes mellitus (GDM). There is a continuity of obesity from childhood to adolescence and then adulthood. However, it is unknown whether early childhood obesity predicts GDM.MethodsWe investigated the prospective association of childhood triceps skinfold thickness and body mass index (BMI) with GDM risk among women from the Mater-University of Queensland Study of Pregnancy (MUSP), a multigenerational cohort study. A multiple logistic regression model was applied to estimate the odds of experiencing GDM by childhood skinfold thickness and BMI.ResultsOut of 552 women in the study for whom data were available on triceps skinfold thickness and BMI at average age 5 (range 3–7) years old, 52 (9.42%) developed GDM by average age 30 (range 28–33) years. We found that the risk of developing GDM was greater among women who had greater skinfold thickness but not greater BMI at age 5 years. Women who were classified as overweight or obese based on skinfold thickness at age 5 years had an increased odds ratio of GDM compared to women who had normal skinfold thickness. This association remained significant after adjustment for the potential confounders (OR 2.74; 95% confidence interval = 1.28–5.86).ConclusionThe risk of developing GDM was associated with higher skinfold thickness at age 5 years. 相似文献
19.
20.
《Vaccine》2022,40(6):904-911
BackgroundGSK initiated a Pregnancy Registry in the United States (US) for the reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap; Boostrix, GSK) vaccine with the aim to detect and describe pregnancy outcomes in women vaccinated with Boostrix 28 days before estimated conception or during pregnancy.MethodsVoluntary reports of pregnancy exposure to Boostrix received from spontaneous and post-marketing surveillance sources in the US were assessed. Reports were classified as prospective or retrospective based on the knowledge of pregnancy outcomes at the time of reporting. For completeness, reports of exposure to Boostrix or to the Tdap-inactivated poliovirus vaccine (Boostrix-IPV, GSK) reported to the global safety database from countries outside the US were also evaluated.ResultsFrom May 2005 to August 2019, 1517 (1455 prospective and 62 retrospective) pregnancy reports were received in the Boostrix US Pregnancy Registry. Of the prospective reports, 250 had known outcomes: 244 live infants with no apparent birth defects (BDs), three live infants with BDs, and three spontaneous abortions with no apparent BDs. Of the retrospective reports, 55 had known outcomes: 33 live infants with no apparent BDs, 16 live infants with BDs, one spontaneous abortion with no apparent BDs, four stillbirths with no apparent BDs, and one stillbirth with BDs. Cumulatively, 1321 pregnancy reports (1006 for Boostrix; 315 for Boostrix-IPV) were received from countries outside the US. Of these, 163 prospective reports and 551 retrospective reports had known outcomes. Results were in line with those from the Boostrix US Pregnancy Registry.ConclusionsData currently available from the Boostrix US Pregnancy Registry and from countries outside the US suggested that exposure to Boostrix or Boostrix-IPV during pregnancy does not raise safety concerns related to adverse pregnancy outcomes or BDs. 相似文献